Finance

Lists
Why is PGEN up 2,76%?
Dive Deeper
PGEN:NASDAQ
Precigen Inc
USD 7,81
+2,76%
(+0,21) 1D
USD 7,81
0,00% (0,00)
After hours
Closed: 9 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PGEN...
Open
USD 7,60
High
USD 7,84
Low
USD 7,48
Mkt. cap
2,80 mjd
Avg. vol.
4,81 m
Volume
3,38 m
52-wk high
USD 8,98
52-wk low
USD 2,99
EPS
-USD 1,10
Beta
0,92
Shares outstanding
358,04 m
No. of employees
160
Open
USD 7,60
High
USD 7,84
Low
USD 7,48
Mkt. cap
2,80 mjd
Avg. vol.
4,81 m
Volume
3,38 m
52-wk high
USD 8,98
52-wk low
USD 2,99
EPS
-USD 1,10
Beta
0,92
Shares outstanding
358,04 m
No. of employees
160
News stories
From web sources and news partners
Profile
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Wikipedia
About Precigen Inc
CEOHelen Sabzevari
Employees160
Founded21 Mei 1998
Headquarters-
Sector-
Websiteprecigen.com
Analyst ratings
Based on 2 analysts giving stock ratings to PGEN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for PGEN in the last 3 months.
Highest
Current USD 7,81
USD 18,00 (+130,47%)
Average
USD 15,00 (+92,06%)
Lowest
USD 12,00 (+53,65%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
USD 18,00
+130,5%
10/01/2026
Yuan Zhi
B. Riley Securities
Buy
Initiated
USD 12,00
+53,6%
09/25/2026
Jason Butler
Citizens JMP
Buy
Maintained
USD 11,00
+40,8%
05/14/2026
Last report
04 Aug. 2026
Fiscal period
Q2 2026
- /
Revenue / Est. (USD)
54,98 m / 27,83 m
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,92 m
4,56 m
23,25 m
54,98 m
Cost of goods sold
13,41 m
8,59 m
8,20 m
10,09 m
Cost of revenue
13,41 m
8,59 m
8,20 m
10,09 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,99 m
17,64 m
21,05 m
22,25 m
Operating expense
23,99 m
17,64 m
21,05 m
22,25 m
Total operating expenses
37,40 m
26,23 m
29,25 m
32,34 m
Operating income
-34,48 m
-21,67 m
-5,99 m
22,64 m
Other non operating income
-111,50 m
60,00 k
290,00 k
16,00 k
EBT including unusual items
-146,34 m
-23,50 m
-7,93 m
20,07 m
EBT excluding unusual items
-146,34 m
-23,50 m
-7,93 m
20,07 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-146,34 m
-23,50 m
-7,93 m
20,07 m
Net profit margin
-5 008,35%
-514,85%
-34,10%
36,51%
Earnings per share
-
-
-
-
Interest and investment income
534,00 k
1,07 m
683,00 k
366,00 k
Interest expense
-902,00 k
-2,96 m
-2,91 m
-2,95 m
Net interest expenses
-368,00 k
-1,90 m
-2,22 m
-2,59 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,68 m
-20,53 m
-4,90 m
23,74 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme